Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient StoriesPatient
StoriesMeet a Real PatientIdentifying Potential PatientsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
Get started with HYMPAVZI (marstacimab-hncq) patient support Co-Pay Savings Program

Co-Pay Savings Program

Pay as little as $0 for treatment. Eligible, commercially insured patients may pay as little as $0 in out-of-pocket costs, with a maximum benefit of $15,000 per calendar year, with the HYMPAVZI Co-pay Savings Program. Enrollment in Pfizer Hemophilia Connect is not required for this program. Terms and conditions apply. This co-pay card is not health insurance and is only available at participating pharmacies.*

 Interim Care Rx Program

Support for eligible patients experiencing delays in insurance coverage. If a delay or coverage denial occurs during the prior authorization or appeals process, eligible commercially insured patients may receive up to 12 months of HYMPAVZI at no cost, shipped directly to the patient through the Interim Care Rx while benefits are being adjudicated. Patients who reside in Minnesota and Rhode Island may receive up to 6 months of HYMPAVZI at no cost. Complete and submit an enrollment form, signed by the patient, to initiate enrollment. Terms and conditions apply.Enroll in Interim Care RxLoadingPatient resources Pfizer Hemophilia Connect offers personalized support for your eligible HYMPAVZI patient, including patient support resources, benefits verification, and guidance through the insurance coverage process.Visit Pfizer Hemophilia ConnectLoading Voucher Program†Help eligible patients to get started with their first prescription. Eligible patients new to HYMPAVZI may receive a free 4-week supply of HYMPAVZI, including the loading dose, shipped directly to them.‡ The voucher is limited to a one-time use per patient. It is not intended to address financial hardship or insurance delays, and cannot be combined with any other savings, free trial, or similar offers for the specified prescription. Terms and conditions apply.Patient savings program Co-Pay Savings Program

Pay as little as $0 for treatment.
Eligible, commercially insured patients may pay as little as $0 in out-of-pocket costs, with a maximum benefit of $15,000 per calendar year, with the HYMPAVZI Co-pay Savings Program. Enrollment in Pfizer Hemophilia Connect is not required for this program. Terms and conditions apply. This co-pay card is not health insurance and is only available at participating pharmacies.*

Patient resources

Interim Care Rx Program

Support for eligible patients experiencing delays in insurance coverage. If a delay or coverage denial occurs during the prior authorization or appeals process, eligible commercially insured patients may receive up to 12 months of HYMPAVZI at no cost, shipped directly to the patient through the Interim Care Rx while benefits are being adjudicated. Patients who reside in Minnesota and Rhode Island may receive up to 6 months of HYMPAVZI at no cost. Complete and submit an enrollment form, signed by the patient, to initiate enrollment. Terms and conditions apply.

Enroll in Interim Care Rx
LoadingPatient resources Patient resources

Pfizer Hemophilia Connect offers personalized support for your eligible HYMPAVZI patient, including patient support resources, benefits verification, and guidance through the insurance coverage process.

Visit Pfizer Hemophilia Connect
Loading Button Loading Button LoadingPatient resources Voucher Program† Help eligible patients to get started with their first prescription. Eligible patients new to HYMPAVZI may receive a free 4-week supply of HYMPAVZI, including the loading dose, shipped directly to them.‡ The voucher is limited to a one-time use per patient. It is not intended to address financial hardship or insurance delays, and cannot be combined with any other savings, free trial, or similar offers for the specified prescription. Terms and conditions apply.*HYMPAVZI Co-Pay Savings Program Full Terms and ConditionsBy using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
  • Eligible patients with commercial prescription drug insurance coverage for HYMPAVZI® may pay as little as $0 per prescription fill. Patient out of pocket expense will vary. The value of this offer is limited to annual benefit of up to $15,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
  • Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patient must have private insurance with coverage. Offer is not valid for cash paying patients.
  • This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
  • This co-pay card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third party insurance.
  • This co-pay card is not valid where prohibited by law.
  • The benefit under the co-pay card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
  • Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the co-pay card program.
  • Co-pay card cannot be combined with any other external savings, free trial, or similar offer for the specified prescription (including any program offered by a third-party payer or pharmacy benefit manager, or an agent of either, that adjusts patient costsharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs).
  • Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the offer co-pay program and/or exclude the financial assistance provided under the offer co-pay program from counting towards patient deductibles or out-of-pocket cost limitations.
  • Co-pay card will be accepted only at participating pharmacies.
  • If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
  • This co-pay is not health insurance.
  • Offer good only in the U.S. and Puerto Rico. 
  • Co-pay card is limited to 1 per person during this offering period and is not transferable.
  • A co-pay card may not be redeemed more than once per 28 days per patient.
  • No other purchase is necessary.
  • Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke or amend this offer without notice.
  • Offer expires 12/31/2027.
  • For questions regarding the offer, please call (1-888-733-2030), visit www.HYMPAVZI.com or write Pfizer Hemophilia Connect, 600 Emerson Road, 3rd Floor, Suite 300, Creve Coeur, MO 63141.

†HYMPAVZI Voucher Terms & Conditions

By redeeming this voucher, you acknowledge that you currently meet the eligibility criteria and will comply with the Terms & Conditions described below:
  • You will receive a one-time, 28-day supply of HYMPAVZI. Only eligible new HYMPAVZI patients may use this voucher, and each patient is limited to 1 voucher.
  • By redeeming this voucher, you certify that you are not currently using HYMPAVZI.
  • An original voucher and a valid prescription must be presented to the pharmacy.
  • The voucher will be accepted only at participating pharmacies.‡
  • You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third-party payor, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
  • You must be 18 years of age or older or be 18 years of age or older and a caregiver of a HYMPAVZI patient.
  • This voucher is not valid where prohibited by law.
  • This voucher cannot be combined with any other savings, free trial, or similar offers for the specified prescription.
  • This free trial voucher is not health insurance. This free trial voucher may not be used to address delays or gaps in health insurance coverage for the specified prescription.
  • Offer good only in the U.S. and Puerto Rico.
  • No purchase is necessary.
  • Patients have no obligation to continue to use HYMPAVZI.
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice. This voucher expires on 12/31/2027.

‡Massachusetts residents may select their pharmacy. Otherwise, this free trial will be supplied through SONEXUS.By redeeming this voucher, you acknowledge that you currently meet the eligibility criteria and will comply with the Terms & Conditions described below:
  • You will receive a one-time, 28-day supply of HYMPAVZI. Only eligible new HYMPAVZI patients may use this voucher, and each patient is limited to 1 voucher.
  • By redeeming this voucher, you certify that you are not currently using HYMPAVZI.
  • An original voucher and a valid prescription must be presented to the pharmacy.
  • The voucher will be accepted only at participating pharmacies.‡
  • You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third-party payor, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
  • You must be 18 years of age or older or be 18 years of age or older and a caregiver of a HYMPAVZI patient.
  • This voucher is not valid where prohibited by law.
  • This voucher cannot be combined with any other savings, free trial, or similar offers for the specified prescription.
  • This free trial voucher is not health insurance. This free trial voucher may not be used to address delays or gaps in health insurance coverage for the specified prescription.
  • Offer good only in the U.S. and Puerto Rico.
  • No purchase is necessary.
  • Patients have no obligation to continue to use HYMPAVZI.
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice. This voucher expires on 12/31/2026.

‡Massachusetts residents may select their pharmacy. Otherwise, this free trial will be supplied through SONEXUS.

HYMPAVZI is a registered trademark of Pfizer Inc.

Resources

Eligible patients can get personalized support through Pfizer Hemophilia Connect

Learn more
Loading

HYMPAVZI is a registered trademark of Pfizer Inc.

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-HYM-USA-1460
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist, and may increase the risk of thromboembolic complications. Venous and arterial thromboembolic events were reported in 0.8% of patients (2/259) in the open-label extension study. Patients with independent risk factors for thromboembolic events may be at increased risk of thromboembolic events with use of HYMPAVZI. Consider the benefit and risk of using HYMPAVZI in patients with known risk factors for thromboembolism. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products or bypassing agents are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose according to the product label is recommended. Inform patients of signs and symptoms of thromboembolic events. Monitor patients for thromboembolic events.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

HYMPAVZI can cause increased levels of fibrin D-dimer and prothrombin fragment 1.2. For patients taking HYMPAVZI, these coagulation biomarkers may not be reliable predictive markers for clinical decision-making with suspicion of thrombosis such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

Adverse reactions reported in ≥2% of patients treated with HYMPAVZI in clinical trials in adult and pediatric patients 6 years and older with hemophilia A or B with or without inhibitors included injection site reaction (12%); headache, including headache and migraine (7%); pyrexia (6%); arthralgia (3%); diarrhea (3%); pruritus (2%); rash (2%).

Consider contacting the Poison Help Line (1-800-222-1222) or a medical toxicologist for overdose management recommendations.IndicationsHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.